Gao Fenghua, Zhang Tingting, Liu Hengqi, Li Wei, Liu Xianming, Qiu Lihua, Li Lanfang, Zhou Shiyong, Qian Zhengzi, Dong Sitong, Zhao Sai, Wang Xianhuo, Zhang Huilai
Department of Lymphoma, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin's Clinical Research Center for Cancer, the Sino-US Center for Lymphoma and Leukemia Research, Huanhuxi Road, Tiyuanbei, Hexi District, Tianjin, 300060, China.
Systematic Review Solutions Ltd, The Ingenuity Centre, Nottingham, UK.
Ann Hematol. 2022 Nov;101(11):2383-2392. doi: 10.1007/s00277-022-04914-8. Epub 2022 Aug 27.
Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, β2m and LDH, total metabolic tumour volume > 510 cm, vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field ≥ 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
24个月内疾病进展(POD24)与滤泡性淋巴瘤(FL)患者的不良预后密切相关。我们的研究旨在确定FL患者POD24的潜在危险因素。系统检索了Medline、EMBASE和Cochrane图书馆,检索时间从最早记录到2020年9月。纳入了调查新诊断的1-3a级FL患者POD24预后因素的研究。在10014篇文献中,共纳入90项研究,调查了82个危险因素进行定性分析。对11个因素的31项研究进行了荟萃分析。结果显示,sIL-2R、β2m和LDH升高、总代谢肿瘤体积>510 cm、维生素D<20 ng/mL、3a级以及淋巴瘤相关巨噬细胞/高倍视野≥15与POD24风险增加显著相关。未发现POD24与ALC/AMC比值、性别、T效应细胞特征或EZH2基因改变之间存在显著关联。此外,对微小残留病、Ki-67、PD-1和TP53进行了描述性分析。总体而言,这是第一项全面分析FL患者中与POD24相关的预后因素的研究。我们已经证实了几个常见预后因素以及其他临床研究中不常包括的因素的意义价值,有助于构建一个综合且更有效的模型。